|
| Home : Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022 |
|
Apr 11
2022 |
Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022 |
|
SAN FRANCISCO and SUZHOU, China, April 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/innovent-release-phase-1-results-of-ibi322-anti-pd-l1cd47-bispecific-antibody-in-patients-with-advanced-solid-tumors-at-aacr-annual-meeting-2022-301522318.html |
| |
|
Related News
|
» Final Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed Against Astra Space, Inc. f/k/a Holicity Inc. (ASTR)
» Musk suggests Twitter changes, including accepting Dogecoin
|
|
|
